Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis

Mukhtar, H; Yasmeen, U; Siddiqa, S; Sarfraz, Z; Sarfraz, A

Sarfraz, Z (通讯作者)，Fatima Jinnah Med Univ, Lahore 54000, Punjab, Pakistan.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022; 65 ():

Abstract

Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS). With limited therapeutics available, this ori......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索